Sprint Bioscience AB (OSTO:SPRINT) Cyclically Adjusted PS Ratio: (As of Jul. 17, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:SPRINT Sprint Bioscience AB OSTO:SPRINT
32 GF Score
Price kr3.72
GF Value kr2.18
Valuation Significantly Overvalued
! 1 Warning Sign
View Full Analysis

What is Sprint Bioscience AB Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Sprint Bioscience AB  (OSTO:SPRINT) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Sprint Bioscience AB Cyclically Adjusted PS Ratio Related Terms


Sprint Bioscience AB Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Sprint Bioscience AB's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sprint Bioscience AB Cyclically Adjusted PS Ratio Chart

Sprint Bioscience AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.67 0.66 0.65

Sprint Bioscience AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.30 0.21 0.26 0.65 0.00

OSTO:SPRINT vs VRTX, REGN, ALNY: Cyclically Adjusted PS Ratio Comparison

For the Biotechnology subindustry, Sprint Bioscience AB's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sprint Bioscience AB Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sprint Bioscience AB's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Sprint Bioscience AB's Cyclically Adjusted PS Ratio falls into.


OSTO:SPRINT
32GF Score
Sprint Bioscience AB OSTO:SPRINT
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sprint Bioscience AB Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Sprint Bioscience AB's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 is calculated as:

For example, Sprint Bioscience AB's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0/133.5600*133.5600
=0.000

Current CPI (Mar. 2026) = 133.5600.

Sprint Bioscience AB Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 1.586 101.019 2.097
201609 0.864 101.138 1.141
201612 1.008 102.022 1.320
201703 0.959 102.022 1.255
201706 0.994 102.752 1.292
201709 0.253 103.279 0.327
201712 0.260 103.793 0.335
201803 1.709 103.962 2.196
201806 0.008 104.875 0.010
201809 0.000 105.679 0.000
201812 0.015 105.912 0.019
201903 0.355 105.886 0.448
201906 1.598 106.742 1.999
201909 0.301 107.214 0.375
201912 0.341 107.766 0.423
202003 0.347 106.563 0.435
202006 0.314 107.498 0.390
202009 0.259 107.635 0.321
202012 0.092 108.296 0.113
202103 0.001 108.360 0.001
202106 0.000 108.928 0.000
202109 0.882 110.338 1.068
202112 0.016 112.486 0.019
202203 0.001 114.825 0.001
202206 0.000 118.384 0.000
202209 0.000 122.296 0.000
202212 0.000 126.365 0.000
202303 0.000 127.042 0.000
202306 0.001 129.407 0.001
202309 0.557 130.224 0.571
202312 0.153 131.912 0.155
202403 0.252 132.205 0.255
202406 0.235 132.716 0.236
202409 0.209 132.304 0.211
202412 0.229 132.987 0.230
202503 0.199 132.825 0.200
202506 0.156 133.699 0.156
202509 0.050 133.480 0.050
202512 1.269 133.390 1.271
202603 0.000 133.560 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Sprint Bioscience AB (OSTO:SPRINT) Overvalued in 2026?

Based on GuruFocus' analysis, Sprint Bioscience AB stock appears to be overvalued. The current stock price of kr3.72 is trading 70.6% above its estimated GF Value™ of kr2.18. GuruFocus considers Sprint Bioscience AB to be Significantly Overvalued.

Key valuation signals for OSTO:SPRINT:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: kr2.18 vs. price of kr3.72 (70.6% above fair value)
  • GF Score™: 32/100 with 1 warning sign

No single metric tells the full story. See the OSTO:SPRINT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Sprint Bioscience AB Business Description

Other Exchanges 5JA1:Germany
Address Halsovagen 7, floor 8, elevator A, Novum, Huddinge, SWE, 141 57
Sprint Bioscience AB is a pharmaceutical company focused on developing drug candidates that can contribute to new treatments for cancer. Its product portfolio includes VRK1, VPS34, PETRA01, TREX1, NNMT, STK25, and DCPS. The company receives revenue for out-licensing drug programs, which include the development of a drug candidate.
32GF Score

Get the complete analysis for OSTO:SPRINT

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr3.72
Price
kr2.18
GF Value